Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3573606 | 0.82 | CNR1 (0.62) | CNR1CNR2 | |
| SCHEMBL3578480 | 0.82 | CNR1 (0.61) | CNR1CNR2 | |
| SCHEMBL4960272 | 0.79 | CNR1 (0.58) | CNR1CNR2 | |
| SCHEMBL3574156 | 0.79 | CNR1 (0.58) | CNR1CNR2 | |
| SCHEMBL3565765 | 0.78 | CNR1 (0.60) | CNR1CNR2 | |
| SCHEMBL3564067 | 0.78 | CNR1 (0.68) | CNR1CNR2 | |
| SCHEMBL3576200 | 0.78 | CNR1 (0.77) | CNR1CNR2 | |
| SCHEMBL4962970 | 0.78 | CNR1 (0.59) | CNR1CNR2 | |
| SCHEMBL3572360 | 0.78 | CNR1 (0.55) | CNR1CNR2 | |
| SCHEMBL3568666 | 0.77 | CNR1 (0.60) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700634-B2 | (Indol-3-yl) heterocycle derivatives as agonists of the cannabinoid CB1 receptor | N.V. ORGANON (NL) | 2010-04-20 | — | — | US | disclosed |
| EP-1725232-B1 | (INDOL-3-YL)-HETEROCYCLE DERIVATIVES AS AGONISTS OF THE CANNABINOID CB1 RECEPTOR | ORGANON NV (NL) | 2008-01-23 | — | — | EP | disclosed |
| US-20070142446-A1 | (Indol-3-yl) heterocycle derivatives as a agonists of the cannabinoid cb1 receptor | MERCK SHARP & DOHME B.V. (NL) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142446-A1 | (Indol-3-yl) heterocycle derivatives as a agonists of the cannabinoid cb1 receptor | CNR1, CNR2, OPRL1 | CNR1 1/4885CNR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.